Profile data is unavailable for this security.
About the company
Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The Company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
- Revenue in EUR (TTM)2.72bn
- Net income in EUR254.70m
- Incorporated1978
- Employees10.60k
- LocationSartorius Stedim Biotech SABp 1051, Aubagne CedexAUBAGNE 13781FranceFRA
- Phone+33 442845600
- Fax+33 442845619
- Websitehttps://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa
More ▼
Mergers & acquisitions
| Acquired company | DIM:PAR since announced | Transaction value |
|---|---|---|
| Polyplus Transfection SA | -31.93% | -- |
Data delayed at least 15 minutes, as of Jul 03 2024 11:10 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amplifon SpA | 2.29bn | 160.70m | 7.58bn | 14.38k | 46.90 | 6.66 | 17.36 | 3.30 | 0.7137 | 0.7137 | 10.16 | 5.03 | 0.6183 | 20.30 | 10.56 | 159,464.60 | 4.34 | 4.31 | 6.35 | 5.81 | 23.78 | 59.01 | 7.03 | 7.28 | 0.4667 | 5.98 | 0.5814 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| Demant A/S | 3.01bn | 342.13m | 8.83bn | 21.62k | 26.06 | 7.10 | -- | 2.94 | 11.44 | 8.05 | 100.58 | 41.97 | 0.7431 | 2.05 | 5.88 | 1,037,923.00 | 8.46 | 8.27 | 12.20 | 13.23 | 73.72 | 74.14 | 11.38 | 11.34 | 0.9529 | 5.98 | 0.6075 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Smith & Nephew plc | 5.16bn | 244.78m | 10.01bn | 18.45k | 40.85 | 2.06 | 11.37 | 1.94 | 0.2375 | 0.2375 | 5.01 | 4.72 | 0.5562 | 0.7522 | 4.33 | 237,089.50 | 2.64 | 4.10 | 3.29 | 4.99 | 68.82 | 71.39 | 4.74 | 8.02 | 0.72 | 4.84 | 0.3715 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | 1.85 |
| BioMerieux SA | 3.67bn | 357.60m | 10.62bn | 14.65k | 29.81 | 2.82 | 17.23 | 2.89 | 3.01 | 3.01 | 30.93 | 31.76 | 0.7036 | 1.97 | 5.00 | 250,815.60 | 6.18 | 9.30 | 7.88 | 12.31 | 55.99 | 56.51 | 8.78 | 12.38 | 1.19 | -- | 0.1215 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sartorius AG | 3.31bn | 148.70m | 14.44bn | 14.34k | 79.65 | 4.45 | 24.73 | 4.36 | 2.18 | 2.18 | 48.85 | 39.05 | 0.3765 | 1.62 | 7.83 | 226,638.80 | 2.51 | 8.21 | 3.43 | 11.83 | 45.11 | 50.93 | 6.65 | 14.15 | 1.28 | 3.41 | 0.5804 | 19.59 | -18.66 | 16.74 | -69.74 | 7.74 | 19.14 | 3.66 |
| Sartorius Stedim Biotech SA | 2.72bn | 254.70m | 14.52bn | 10.60k | 54.61 | 3.59 | 28.07 | 5.34 | 2.73 | 2.73 | 29.11 | 41.57 | 0.4013 | 1.60 | 7.82 | 254,764.60 | 3.81 | 11.87 | 4.55 | 15.12 | 42.98 | 50.96 | 9.49 | 17.44 | 1.24 | 6.59 | 0.452 | 18.73 | -20.53 | 18.02 | -64.65 | 8.28 | 21.82 | 3.90 |
| Sonova Holding AG | 3.73bn | 618.77m | 17.14bn | 18.15k | 27.79 | 6.74 | 19.46 | 4.59 | 10.05 | 10.05 | 60.66 | 41.44 | 0.6394 | 2.35 | 6.82 | 199,818.20 | 10.75 | 10.87 | 13.45 | 13.88 | 72.28 | 71.97 | 16.80 | 17.77 | 1.07 | 31.44 | 0.4268 | 35.21 | -2.98 | 5.59 | -5.84 | 5.77 | 1.75 | 8.20 |
| Straumann Holding AG | 2.48bn | 253.35m | 18.72bn | 11.11k | 73.98 | 9.90 | 48.23 | 7.54 | 1.54 | 1.54 | 15.11 | 11.52 | 0.7204 | 1.81 | 4.29 | 217,105.00 | 7.37 | 10.68 | 9.86 | 13.63 | 74.15 | 74.95 | 10.23 | 15.15 | 1.43 | 6.72 | 0.1968 | 37.50 | 3.92 | 12.08 | -43.40 | -2.04 | 11.54 | 10.12 |
Data as of Jul 03 2024. Currency figures normalised to Sartorius Stedim Biotech SA's reporting currency: Euro EUR
6.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Comgest SAas of 29 Feb 2024 | 1.13m | 1.16% |
| Fidelity Management & Research Co. LLCas of 06 Jun 2024 | 982.20k | 1.01% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 908.45k | 0.93% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 742.98k | 0.76% |
| Baillie Gifford & Co.as of 31 May 2024 | 700.84k | 0.72% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 555.51k | 0.57% |
| Capital International Ltd.as of 31 Mar 2024 | 518.08k | 0.53% |
| T. Rowe Price International Ltd.as of 31 Mar 2024 | 489.15k | 0.50% |
| Invesco Advisers, Inc.as of 31 May 2024 | 356.50k | 0.37% |
| Select Equity Group LPas of 31 May 2024 | 355.84k | 0.37% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
